In 2018, three independent studies demonstrated that intestinal microbiome profoundly affected responses to anti-programmed cell death protein 1 (anti-PD-1)/anti-PD-L1 immunotherapy in patients with melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma2–4. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.